Нюансы антикоагулянтной терапии у пациентов с хронической болезнью почек и фибрилляцией предсердий

Скорость клубочковой фильтрации (СКФ) снижается с возрастом после 50 лет. Число пациентов с фибрилляцией предсердий (ФП) и хронической болезнью почек (ХБП) ежегодно увеличивается. Риск развития ишемического инсульта и тромбоэмболических осложнений, как и риск кровотечений, значительно выше у пациентов с ФП при наличии у них сопутствующей дисфункции почек. Результаты четырех рандомизированных клинических исследований (РКИ) продемонстрировали преимущества новых прямых пероральных антикоагулянтов (ППОАК) по сравнению с варфарином, однако эти РКИ имели серьезные ограничения, обусловленные включением относительно низкой доли пациентов с выраженной ХБП. Исследование ROCKET-AF отличалось от других РКИ (RE-LY, ARISTOTLE) более высокими рисками у пациентов с ФП, оцененными по шкалам CHADS₂ и HAS-BLED. Международное нормализованное отношение, находящееся вне терапевтического окна, ассоциировано с ухудшением функции почек у лиц с ФП, принимающих варфарин. У пациентов с клинически значимой дисфункцией почек необходимо уменьшение дозы ППОАК, так как все ППОАК в определенной мере выводятся почками. Пренебрежение рекомендациями в уменьшении дозы ППОАК у пациентов со сниженной функцией почек может привести к повышению риска кровотечений, и, наоборот, некорректное снижение дозы без четких показаний может снизить эффективность ППОАК в профилактике инсульта. В данной статье обсуждаются фармакологические характеристики ППОАК в зависимости от степени нарушения функции почек, важные нюансы при выборе антикоагулянтной терапии ППОАК у пациентов с сосуществующими ФП и ХБП.

фибрилляция предсердий, антикоагулянты, ривароксабан, ухудшение функции почек, atrial fibrillation, anticoagulants, rivaroxaban, deteriorating renal function

1. Banerjee A., Marin F., Lip G. Y. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. Stroke 2011;42:3316-3322.

2. Marinigh R., Lane D. A., Lip G. Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J. Am Coll Cardiol 2011;57:1339-1348.

3. Saran R., Robinson B., Abbott K. C. et al. US Renal Data System 2017 Annual Data Report: epidemiology of kidney disease in the United States. AmJ Kidney Dis 2018;71 (3) (suppl 1):Svii, S1-S672.

4. Сулимов В. А., Голицын С. П., Панченко Е. П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал 2013;4 (прил. 3):1-100

5. USRDS 2006 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: U. S. Renal Data System, 2006.

6. Lee M., Saver J. L., Chang K. H. et al. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010;341: c4249.

7. Steffel J., Verhamme P., Potpara T. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K. antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;00:1-64.

8. Wizemann V., Tong L., Satayathum S. et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77 (12):1098-106.

9. Chan K. E., Lazarus J. M., Thadhani R., Hakim R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am Soc Nephrol 2009;20:2223-2233.

10. Yang F., Chou D., Schweitzer P., Hanon S. Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 2010;12:1666-1672.

11. Atar I., Konas D., Acikel S. et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 2006;106:47-51.

12. Brodsky S. V., Nadasdy T., Rovin B. H. et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011;80:181-189.

13. Brodsky S. V., Collins M., Park E. et al. Warfarin therapy that results in an international normalization ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010;115:142-146.

14. Granger C. B., Alexander J. H., McMurray J. J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.

15. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.

16. Patel M. R., Mahaffey K. W., GargJ. et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011;365:883-891.

17. Giugliano R. P., Ruff C. T., Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104.

18. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507.

19. Chugh S. S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-847.

20. Krijthe B. P., Kunst A., Benjamin E.J. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34:2746-2751.

21. Heeringa J., van der Kuip D. A., Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27980:949-953.

22. Davies D. F., Shock N. W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950;29:496-507.

23. IDF. IDF Diabetes Atlas. 6th ed 2013. https://www.idf.org e-library / epidemiology-research/diabetes-atlas /19-atlas-6th-edition. html (10 July 2018).

24. Baber U., Howard V.J., Halperin J. L. et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011;4:26-32.

25. Soliman E. Z., Prineas R.J., Go A. S. et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102-1107.

26. Iguchi Y., Kimura K., Kobayashi K. et al. Relation of atrial fibrillation to glomerular filtration rate. AmJ Cardiol 2008;102 (8):1056-1059.

27. Alonso A., Lopez F. L., Matsushita K. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123 (25):2946-2953.

28. Wolf P. A., Abbott R. D., Kannel W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.

29. Benjamin E.J., Wolf P. A., D»Agostino R. B. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952.

30. Go A. S., Hylek E. M., Phillips K. A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-2375.

31. Vazquez E., Sanchez-Perales C., Garcia-Garcia F. et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009;76:324-330.

32. Schaeffner E. S., Ebert N., Delanaye P. et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012;157:471-481.

33. Stevens L. A., Coresh J., Greene T., Levey A. S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483.

34. Go A. S., Chertow G. M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.

35. Go A. S., Fang M. C., Udaltsova N. et al.; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-1369.

36. Guo Y., Wang H., Zhao X. et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 2013;168:4678-4684.

37. Pontorieri G., Santoro D., Messina A. et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): results of the Italian cohort. G Ital Nefrol 2005;22 (5):494-502.

38. Vazquez E., Sanchez-Perales C., Garcia-Cortes M.J. et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol 2003;87:135-139.

39. Kumai Y., Kamouchi M., HataJ. et al.; FSR Investigators. Proteinuria and clinical outcomes after ischemic stroke. Neurology 2012;78:1909-1915.

40. Yahalom G., Schwartz R., Schwammenthal Y. et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 2009;40:1296-1303.

41. Corrao S., Argano C., Nobili A. et al., REPOSI Investigators Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. Eur J Intern Med 2015;26:243-249.

42. Abbott K. C., Trespalacios F. C., Taylor A.J., Agodoa L. Y. Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC Nephrol 2003;4:1-10.

43. Vazquez E., Sanchez-Perales C., Lozano C. et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003;92:868-871.

44. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007;146 (12):857-867.

45. Bonde A. N., Lip G. Y., Kamper A. L. et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471-2482.

46. Olesen J. B., Lip G. Y., Kamper A. L. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-635.

47. Chan K. E., Lazarus J. M., Thadhani R., Hakim R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-2233.

48. Spetie D. N., Nadasdy T., Nadasdy G. et al. Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis 2006;47:419-427.

49. Koos R., Krueger T., Westenfeld R. et al. Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009;101:706-713.

50. Bos M.J., Koudstaal P.J., Hofman A., Breteler M. M. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007;38:3127-3132.

51. Shimizu Y., Maeda K., Imano H. et al. Chronic kidney isease and drinking status in relation to risks of stroke and its subtypes: the Circulatory Risk in Communities Study (CIRCS). Stroke 2011;42:2531-2537.

52. Wasse H., Gillen D. L., Ball A. M. et al. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 2003;64:1455-1461.

53. Ovbiagele B., Wing J.J., Menon R. S. et al. Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage. Stroke 2013;44:2409-2413.

54. Kuo C. C., Kuo H. W., Lee I. M. et al. The risk of upper gastrointestinalbleeding in patients treated with hemodialysis: a population-based cohort study. BMC Nephrol 2013;14:15. https://doi.org/10.1186/1471-2369-14-15.

55. Sood P., Kumar G., Nanchal R. et al. Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. Am J. Nephrol 2012;35:216-224.

56. Limdi N. A., Beasley T. M., Baird M. F. et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J. Am Soc Nephrol 2009;20:912-921.

57. Kubitza D., Becka M., Mueck W. et al. Impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J. Clin Pharmacol 2010;70 (5):703-712.

58. Raghavan N., Frost C. E., Yu Z. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37 (1):74-81.

59. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, singlecentre study. Clin Pharmacokinet 2010;49:259-268.

60. Mueck W., Lensing A., Agnelli G. et al. Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50 (10):675-686.

61. Sherwood M. W., Nessel C. C., Hellkamp A. S. et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF Trial. JACC 2015;66 (21):2271-2281.

62. Kirchhof P., Radaideh G., Kim Y. H. et al. Safety analysis of rivaroxaban: a pooled analysis of the global XANTUS programme (real-world, prospective, observational studies for stroke prevention in patients with atrial fibrillation). Eur Heart J. 2017;38 (Suppl.): 768-769.

63. Fox K. A., Piccini J. P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394.

64. Лукьянов М. М., Бойцов С. А., Якушин C. С. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным РЕгистра КардиоВАскулярных ЗАболеваний РЕКВАЗА). Рациональная фармакотерапия в кардиологии 2014;10 (4):366-377

65. Fordyce C. B., Hellkamp A. S., Lokhnygina Y. et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation 2016;134:37-47.

66. Hijazi Z., Hohnloser S. H., Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY trial analysis. Circulation. 2014;129 (9):961-970. https://doi.org/10.1161/CIRCULATIONAHA. 113.003628.

67. Böhm M., Ezekowitz M. D., Connolly S. et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. JACC 2015;65 (23):2481-2493.

68. Hijazi Z., Hohnloser S. H., Andersson U. et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relationto Renal Function Over Time Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016;1 (4):451-460. https://doi.org/10.1001/jamacardio. 2016.1170.

69. Yao X., Tangri N., Gersh B. J. et al. Renal outcomes in anticoagulated patients with atrial fibrillation. Am Coll Cardiol 2017;70:2621-2632.

70. Nguyen E., White C. M., Patel M. R. et al. Doses of apixaban and rivaroxaban prescribed in real-world united states cardiology practices compared to registration trials. Curr Med Res Opin 2016;32 (7):1277-1279. https://doi.org/10.1185/03007995.2016.1170672.

71. IMS Health MIDAS database. Q42015. https://www.investor.bay-er.de/en/handouts/archive-investor-handouts

72. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609-1678.

73. Yao X., Shah N. D., Sangaralingham L. R. et al. Non-vitamin K. antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J. Am Coll Cardiol 2017;69 (23):2779-2790.

74. Nielsen P. B., Skjoth F., S0gaard M. et al. Effectiveness and safety of reduced dose non-vitamin K. antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017;356: j510 https://doi.org/10.1136/bmj. j510.

75. Camm A.J., Amarenco P., Haas S. et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145-1153.

76. Steinberg B. A., Holmes D. N., Piccini J. P. et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J. Am Heart Assoc 2013;2: e000535.

77. Chang H. Y., Zhou M., Tang W. et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350: h1585.

78. Peacock W. F., Tamayo S., Patel M. et al. CHA2DS2ASc scores and major bleeding in patients with nonvalvular atrial fibrillation who are receiving rivaroxaban. Ann Emerg Med 2017;69:541-550.